BRPI0419032B8 - composição farmacêutica de liberação prolongada de hidralazina - Google Patents

composição farmacêutica de liberação prolongada de hidralazina

Info

Publication number
BRPI0419032B8
BRPI0419032B8 BRPI0419032A BRPI0419032A BRPI0419032B8 BR PI0419032 B8 BRPI0419032 B8 BR PI0419032B8 BR PI0419032 A BRPI0419032 A BR PI0419032A BR PI0419032 A BRPI0419032 A BR PI0419032A BR PI0419032 B8 BRPI0419032 B8 BR PI0419032B8
Authority
BR
Brazil
Prior art keywords
hydralazine
extended
pharmaceutical composition
release pharmaceutical
allows
Prior art date
Application number
BRPI0419032A
Other languages
English (en)
Inventor
Mohar Betancourt Alejandro
Dueñas González Alfonso
Rivera Hernández Alfredo
Borbolla García Arturo
Estrada Flores Luis
Serna Martínez Raúl
Original Assignee
Psicofarma S A De C V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Psicofarma S A De C V filed Critical Psicofarma S A De C V
Publication of BRPI0419032A publication Critical patent/BRPI0419032A/pt
Publication of BRPI0419032B1 publication Critical patent/BRPI0419032B1/pt
Publication of BRPI0419032B8 publication Critical patent/BRPI0419032B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

composição farmacêutica de liberação prolongada de hidralazina e seu uso como apoio para o tratamento do câncer. a presente invenção se refere a uma forma de liberação prolongada de hidralazina para se utilizar na terapia contra o câncer. esta forma de liberação prolongada de hidralazina permite que se alcance no sangue uma concentração constante do princípio ativo que permite que se apresente o efeito desmetilante da hidralazina sem que apareça sua ação hipotensora, o que permite seu uso na terapia contra o câncer.
BRPI0419032A 2004-09-09 2004-09-09 composição farmacêutica de liberação prolongada de hidralazina BRPI0419032B8 (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/MX2004/000064 WO2006028362A1 (es) 2004-09-09 2004-09-09 Composición farmacéutica de liberación prolongada de hidralazina y su uso como apoyo para el tratamiento del cáncer

Publications (3)

Publication Number Publication Date
BRPI0419032A BRPI0419032A (pt) 2007-12-11
BRPI0419032B1 BRPI0419032B1 (pt) 2019-02-05
BRPI0419032B8 true BRPI0419032B8 (pt) 2021-05-25

Family

ID=36036613

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0419032A BRPI0419032B8 (pt) 2004-09-09 2004-09-09 composição farmacêutica de liberação prolongada de hidralazina

Country Status (17)

Country Link
US (1) US7820200B2 (pt)
EP (1) EP1803447B1 (pt)
JP (1) JP4814885B2 (pt)
CN (1) CN101039661A (pt)
BR (1) BRPI0419032B8 (pt)
CA (1) CA2579220C (pt)
CR (1) CR9035A (pt)
CY (1) CY1110508T1 (pt)
DE (1) DE602004022205D1 (pt)
DK (1) DK1803447T3 (pt)
ES (1) ES2330227T3 (pt)
MX (1) MX2007002871A (pt)
NZ (1) NZ554360A (pt)
PL (1) PL1803447T3 (pt)
PT (1) PT1803447E (pt)
SI (1) SI1803447T1 (pt)
WO (1) WO2006028362A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016020901A1 (en) 2014-08-07 2016-02-11 Acerta Pharma B.V. Methods of treating cancers, immune and autoimmune diseases, and inflammatory diseases based on btk occupancy and btk resynthesis rate

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK150008C (da) 1981-11-20 1987-05-25 Benzon As Alfred Fremgangsmaade til fremstilling af et farmaceutisk oralt polydepotpraeparat
US4521402A (en) * 1983-01-03 1985-06-04 Verex Laboratories, Inc. Constant release rate solid oral dosage formulations of hydrazine
US4461759A (en) * 1983-01-03 1984-07-24 Verex Laboratories, Inc. Constant release rate solid oral dosage formulations of veropamil
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
GB8624213D0 (en) * 1986-10-09 1986-11-12 Sandoz Canada Inc Sustained release pharmaceutical compositions
CZ2006443A3 (cs) * 1999-03-31 2019-02-20 Janssen Pharmaceutica N. V. Hydrofilní formulace s řízeným uvolňováním, která obsahuje předželatinovaný škrob, způsob její přípravy a léková forma s jejím obsahem
US20030091630A1 (en) * 2001-10-25 2003-05-15 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
US20050226926A1 (en) * 2002-07-25 2005-10-13 Pfizer Inc Sustained-release tablet composition of pramipexole
JPWO2004037293A1 (ja) * 2002-10-22 2006-02-23 大日本住友製薬株式会社 安定化組成物

Also Published As

Publication number Publication date
SI1803447T1 (sl) 2010-01-29
EP1803447B1 (en) 2009-07-22
US7820200B2 (en) 2010-10-26
CN101039661A (zh) 2007-09-19
CR9035A (es) 2009-03-27
US20090042889A1 (en) 2009-02-12
JP2008512450A (ja) 2008-04-24
BRPI0419032B1 (pt) 2019-02-05
WO2006028362A1 (es) 2006-03-16
DK1803447T3 (da) 2009-10-12
EP1803447A1 (en) 2007-07-04
BRPI0419032A (pt) 2007-12-11
CA2579220C (en) 2013-01-08
PT1803447E (pt) 2009-08-14
DE602004022205D1 (de) 2009-09-03
JP4814885B2 (ja) 2011-11-16
ES2330227T3 (es) 2009-12-07
PL1803447T3 (pl) 2010-05-31
CY1110508T1 (el) 2015-04-29
CA2579220A1 (en) 2006-03-16
MX2007002871A (es) 2007-04-23
NZ554360A (en) 2009-11-27

Similar Documents

Publication Publication Date Title
AR109605A2 (es) Método para tratar enfermedades vasculares periféricas, composición y utilización
BR112014031394A8 (pt) Composições compreendendo ciclobenzaprina ou amitriptilina e seus usos via absorção transmucosa oral
HN2004000490A (es) Procedimiento para la preparacion de una composicion farmaceutica solida administrable oralmente
AR068185A1 (es) Composiciones de tabletas de desintegracion oral de lamotrigina
DOP2010000304A (es) Composiciones y metodos de preparacion y uso de las mismas
NZ606825A (en) Methods and compositions for treating complement-associated disorders
MX2009003122A (es) Inhibidores de tirosina cinasa de bruton.
BRPI0618239A8 (pt) uso de flibanserina para o tratamento de distúrbios de desejo sexual pré-menopáusicos
CL2011002248A1 (es) Composicion farmaceutica oral de liberacion inmediata que comprende oxicodona y naloxona en una proporcion 2:1 en peso; uso de la composicion farmaceutica para tratar dolor intercurrente en paciente que sufren de dolor.
AR061171A1 (es) Proteinas de union al factor de crecimiento de hepatocitos (fch)
AR047928A1 (es) Derivados de tetrahidropiridoindol
ECSP088763A (es) Nuevas combinaciones terapéuticas para el tratamiento de la depresión
BRPI0806863B8 (pt) uso de um éster de forbol na preparação de um medicamento para prevenção ou tratamento de uma infecção por hiv
CY1115725T1 (el) Ενωσεις, συνθεσεις και μεθοδοι για την θεραπευτικη αγωγη των βητα-αμυλοειδικων ασθενειων και συνουκλεϊνοπαθειων
AR077125A1 (es) Combinaciones farmaceuticas utiles para tratar el vhc
AR077138A1 (es) Composiciones farmaceuticas utiles para tratar el vhc
CL2008002545A1 (es) Compuestos derivados de fenoxi-bencil-carbamoilo; composicion farmaceutica; procedimiento para preparar la composicion farmaceutica; y su uso en el tratamiento del dolor.
BR112012014159A2 (pt) Combinações terapêuticas de teobromina e um anti-histamínico
CL2008002060A1 (es) Compuestos derivados de sulfonamida, inhibidores de la produccion de beta amiloide; metodo de preparacion; composicion farmaceutica; kit farmaceutico; y uso en el tratamiento de enfermedades tales como alzheimer, angiopatia amiloide, sindrome de down, entre otras.
EA200602002A1 (ru) Применение спинозинов для заживления ран
PE20061051A1 (es) Composicion farmaceutica que comprende mirtazapina s
BRPI0606528A2 (pt) composição para uso no fabrico de medicamentos de tratamento da infertilidade masculina e uso da mesma
BRPI0419032B8 (pt) composição farmacêutica de liberação prolongada de hidralazina
EA200801890A1 (ru) Средство для лечения шума в ушах
AR047154A1 (es) Tratamiento del insomnio en pacientes humanos administrandoles una cantidad diaria de gaboxadol

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 05/02/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 05/02/2019, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 09/09/2004 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 20A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2791 DE 02-07-2024 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.